Cargando…

Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo

BACKGROUND: Nifurtimox eflornithine combination therapy (NECT) to treat human African trypanosomiasis (HAT), commonly called sleeping sickness, was added to the World Health Organisation’s (WHO) Essential Medicines List in 2009 and to the Paediatric List in 2012. NECT was further tested and document...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuemmerle, Andrea, Schmid, Caecilia, Kande, Victor, Mutombo, Wilfried, Ilunga, Medard, Lumpungu, Ismael, Mutanda, Sylvain, Nganzobo, Pathou, Ngolo, Digas, Kisala, Mays, Valverde Mordt, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004379/ https://www.ncbi.nlm.nih.gov/pubmed/31986140 http://dx.doi.org/10.1371/journal.pntd.0008028

Ejemplares similares

In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness
por: Schmid, Caecilia, et al.
Publicado: (2012)

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study
por: Kuemmerle, Andrea, et al.
Publicado: (2021)

Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection
por: Ngay Lukusa, Ipos, et al.
Publicado: (2021)

Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
por: Kande Betu Kumesu, Victor, et al.
Publicado: (2022)

Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study
por: Ngay Lukusa, Ipos, et al.
Publicado: (2022)

A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda
por: Kansiime, Freddie, et al.
Publicado: (2018)

720. Efficacy of Nifurtimox + Eflornithine in the Treatment of African Trypanosomiasis. Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

How Clinical Research Can Contribute to Strengthening Health Systems in Low Resource Countries
por: Mbo, Florent, et al.
Publicado: (2020)

Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series
por: Checchi, Francesco, et al.
Publicado: (2007)

Untargeted Metabolomics Reveals a Lack Of Synergy between Nifurtimox and Eflornithine against Trypanosoma brucei
por: Vincent, Isabel M., et al.
Publicado: (2012)

Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis: A Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness
por: Yun, Oliver, et al.
Publicado: (2010)

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
por: Betu Kumeso, Victor Kande, et al.
Publicado: (2023)

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
por: Kande Betu Ku Mesu, Victor, et al.
Publicado: (2021)

Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6
por: Baker, Nicola, et al.
Publicado: (2011)

An Active Follow-up Strategy for Serological Suspects of Human African Trypanosomiasis with Negative Parasitology Set up by a Health Zone Team in the Democratic Republic of Congo
por: Nkieri, Matthieu, et al.
Publicado: (2020)

Enantiospecific antitrypanosomal in vitro activity of eflornithine
por: Boberg, Mikael, et al.
Publicado: (2021)

Diagnostic Accuracy of PCR in gambiense Sleeping Sickness Diagnosis, Staging and Post-Treatment Follow-Up: A 2-year Longitudinal Study
por: Deborggraeve, Stijn, et al.
Publicado: (2011)

Communities’ Perception, Knowledge, and Practices Related to Human African Trypanosomiasis in the Democratic Republic of Congo
por: Kabanga, Charlie, et al.
Publicado: (2022)

The Adaptation and Feasibility of Narrative Enhancement and Cognitive Therapy (NECT) for Late-Onset Psychosis
por: Ching, Elaine Y. N., et al.
Publicado: (2019)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
por: Vincent, Isabel M., et al.
Publicado: (2010)

KKI-NECT: Kennedy krieger institute’s network for early childhood tele-education (US)
por: Leppert, M., et al.
Publicado: (2021)

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas
por: Levin, Victor A, et al.
Publicado: (2018)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

Performance of Parasitological and Molecular Techniques for the Diagnosis and Surveillance of Gambiense Sleeping Sickness
por: Mumba Ngoyi, Dieudonné, et al.
Publicado: (2014)

Specificity of malaria rapid diagnostic tests is affected by Trypanosoma brucei gambiense sleeping sickness
por: Gillet, Philippe, et al.
Publicado: (2012)

Treatment options for second-stage gambiense human African trypanosomiasis
por: Eperon, Gilles, et al.
Publicado: (2014)

Soil gross nitrogen transformations along the Northeast China Transect (NECT) and their response to simulated rainfall events
por: Zhang, Jin-bo, et al.
Publicado: (2016)

Correction to “Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox”
por: Lang, Dieter, et al.
Publicado: (2023)

Identifying regions for enhanced control of gambiense sleeping sickness in the Democratic Republic of Congo
por: Huang, Ching-I, et al.
Publicado: (2022)

Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells
por: Yam, Noymi, et al.
Publicado: (2020)

Safety and efficacy of hydroxyurea and eflornithine against most blood parasites Babesia and Theileria
por: El-Saber Batiha, Gaber, et al.
Publicado: (2020)

Application of Hantzsch reaction for sensitive determination of eflornithine in cream, plasma and urine samples
por: Almahri, Albandary, et al.
Publicado: (2021)

Gambiense Human African Trypanosomiasis and Immunological Memory: Effect on Phenotypic Lymphocyte Profiles and Humoral Immunity
por: Lejon, Veerle, et al.
Publicado: (2014)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo
por: Crump, Ronald E., et al.
Publicado: (2021)

African Trypanosomiasis Gambiense, Italy
por: Bisoffi, Zeno, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ae519i5eb7pb43igroj85mi2j0